Arun Balakumaran

机构：Allogene Therapeutics (United States)

发表论文 110 篇 · 总被引 5641 次 · h-index 34

代表论文

• Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma (2017 · Journal of Clinical Oncology · 被引 998)
• Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure (2016 · Journal of Clinical Oncology · 被引 674)
• Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 (2019 · Blood · 被引 336)
• Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (2017 · Blood · 被引 296)
• Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (2019 · Journal of Clinical Oncology · 被引 266)
• Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (2023 · Nature Medicine · 被引 259)